2 weeks Ago By Defense World Staff
Mirum Pharmaceuticals ( NASDAQ:MIRM – Get Free Report ) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $66.00 price target on the stock.
HC Wainwright’s price target would indicate a potential upside of 42.67% from the company’s current price. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2025 earnings at $0.
35 EPS and Q4 2025 earnings at $0.61 EPS. A number of other research firms also recently issued reports on MIRM.
Cantor Fitzgerald raised their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th.
Evercore ISI boosted their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th.
Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday.
Leerink Partners lifted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th.
Finally, Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.
00 and gave the stock an “outperform” rating in a report on Wednesday. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Buy” and an average price target of $57.
73. Check Out Our Latest Analysis on MIRM Mirum Pharmaceuticals Price Performance Mirum Pharmaceuticals ( NASDAQ:MIRM – Get Free Report ) last released its earnings results on Tuesday, November 12th. The company reported ($0.
30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15.
Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%.
The firm had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million.
During the same period in the previous year, the company earned ($0.57) earnings per share. The company’s quarterly revenue was up 89.
4% on a year-over-year basis. On average, equities research analysts forecast that Mirum Pharmaceuticals will post -1.84 earnings per share for the current year.
Institutional Trading of Mirum Pharmaceuticals A number of hedge funds have recently bought and sold shares of MIRM. Erste Asset Management GmbH purchased a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $10,136,000. PDT Partners LLC boosted its position in Mirum Pharmaceuticals by 188.
9% during the third quarter. PDT Partners LLC now owns 113,712 shares of the company’s stock valued at $4,435,000 after buying an additional 74,349 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Mirum Pharmaceuticals by 5.
7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,461 shares of the company’s stock valued at $2,475,000 after buying an additional 3,442 shares during the last quarter. FORA Capital LLC purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $399,000.
Finally, Loomis Sayles & Co. L P bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $19,473,000. About Mirum Pharmaceuticals ( Get Free Report ) Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Read More Five stocks we like better than Mirum Pharmaceuticals 3 Small Caps With Big Return Potential 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Are Penny Stocks a Good Fit for Your Portfolio? Mouse Rising: The Iger Investment Pays Off for Disney Investors The 3 Best Blue-Chip Stocks to Buy Now Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
